Is Selling 52-Week Stock Like Microbot Medical Inc (MBOT) a Winning Strategy?

July 17, 2017 - By Darrin Black

The stock of Microbot Medical Inc (NASDAQ:MBOT) hit a new 52-week low and has $1.05 target or 9.00 % below today’s $1.15 share price. The 7 months bearish chart indicates high risk for the $33.20M company. The 1-year low was reported on Jul, 17 by If the $1.05 price target is reached, the company will be worth $2.99M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 501,237 shares traded. Microbot Medical Inc (NASDAQ:MBOT) has declined 86.60% since July 17, 2016 and is downtrending. It has underperformed by 103.30% the S&P500.

More notable recent Microbot Medical Inc (NASDAQ:MBOT) news were published by: which released: “Microbot Medical: ~$250 Million Market Cap… Irrational Exuberance At Its Best” on January 12, 2017, also with their article: “1.17” published on December 16, 2016, published: “Stemcell Merger: Why It Happened” on August 17, 2016. More interesting news about Microbot Medical Inc (NASDAQ:MBOT) were released by: and their article: “Microbot Medical Inc.” published on November 29, 2016 as well as‘s news article titled: “Microbot Medical Announces Closing of $10 Million Registered Direct Offering …” with publication date: June 09, 2017.

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The company has market cap of $33.20 million. The Firm specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It currently has negative earnings. It is engaged in developing its two product candidates: the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.